HBM Holdings Limited (HKG:2142)

Market Cap	7.36B
Revenue (ttm)	295.94M
Net Income (ttm)	21.58M
Shares Out	799.49M
EPS (ttm)	0.03
PE Ratio	340.87
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,463,000
Average Volume	7,274,660
Open	9.27
Previous Close	9.27
Day's Range	9.05 - 9.44
52-Week Range	1.06 - 10.00
Beta	1.76
RSI	60.65
Earnings Date	May 28, 2025

About HBM Holdings

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel antibody therapeutics in immunology and oncology disease areas. It has developed the Harbour Mice Platform, which generates fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 and heavy chain formats. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific anti...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 183
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2024, HBM Holdings's revenue was $38.10 million, a decrease of -57.43% compared to the previous year's $89.50 million. Earnings were $2.78 million, a decrease of -87.81%.

Financial numbers in USD